Bamlanivimab prevents COVID-19 morbidity and mortality in nursing-home setting | Topics in Antiviral Medicine; 29(1):32-33, 2021. | EMBASE

Bamlanivimab was highly effective in reducing the incidence of symptomatic COVID-19 and SARS-CoV-2 infection and was well tolerated. These findings demonstrate the potential beneficial impact of bamlanivimab use on COVID-19 morbidity and mortality among skilled nursing facility residents. Source: Bamlanivimab prevents COVID-19 morbidity and mortality in nursing-home setting | Topics in Antiviral Medicine; 29(1):32-33, 2021. | EMBASE